Skip to main content

Spring Bank discontinues hepatitis drug after patient death in trial

Spring Bank Pharmaceuticals said on Wednesday it has discontinued the development of its experimental drug to treat chronic hepatitis B virus (HBV), following the death of a patient in a mid-stage trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.